Relapse and long-acting injectable risperidone

A 1-year mirror image study with a national claims database in Taiwan

Kuan Pin Su, Hui Chih Chang, Shih Jen Tsai, Feng Chang Yen, Chao Hsiun Tang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives: The development of long-acting, injectable atypical antipsychotics has provided a new paradigm for schizophrenia treatment. The study was designed to assess whether a risperidone long-acting injection (RLAI) is associated with reduced relapses and service utilization in the real world. Methods: The Psychiatric Inpatients Medical Claims dataset was used for the analysis. It is a longitudinal dataset that includes the National Health Insurance claims of service uses by a cohort of mentally ill patients. The inclusion criteria for this analysis were patients who: 1) had available information for at least 12 months after the first dose of RLAI; 2) had a primary diagnosis of schizophrenia; and 3) were regularly treated with RLAI for at least 1 year. Patients who accumulatively received at least 75-mg RLAI per 3-month period were considered to be undergoing regular treatment. Wilcoxon signed rank tests were performed to compare differences in numbers of acute admissions, hospital days, emergency room visits, and relapses between the pre- and post-RLAI periods in this 1-year mirror-image study. Results: In total, 108 patients were eligible for analysis. Significant reductions in the total annual numbers of acute hospital admissions by 55% (80 vs. 36, P = 0.0003), hospital days by 48% (4106 vs. 2126, P = 0.0021), and relapses by 54% (115 vs. 53, P = 0.0005) were observed. A reduction of emergency room visits was also observed, but did not reach statistical significance (55 vs. 25, P = 0.1255). Conclusions: This 1-year mirror-image analysis with claims-based data demonstrated that RLAI treatment was associated with reductions in relapses and hospital service utilization.

Original languageEnglish
JournalValue in Health
Volume12
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Risperidone
Taiwan
Databases
Recurrence
Injections
Hospital Emergency Service
Schizophrenia
Insurance Claim Review
Mentally Ill Persons
National Health Programs
Nonparametric Statistics
Antipsychotic Agents
Psychiatry
Inpatients
Therapeutics

Keywords

  • National Health Insurance
  • Relapse
  • Risperidone long-acting injection
  • Schizophrenia
  • Taiwan

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Relapse and long-acting injectable risperidone : A 1-year mirror image study with a national claims database in Taiwan. / Su, Kuan Pin; Chang, Hui Chih; Tsai, Shih Jen; Yen, Feng Chang; Tang, Chao Hsiun.

In: Value in Health, Vol. 12, No. SUPPL. 3, 11.2009.

Research output: Contribution to journalArticle

Su, Kuan Pin ; Chang, Hui Chih ; Tsai, Shih Jen ; Yen, Feng Chang ; Tang, Chao Hsiun. / Relapse and long-acting injectable risperidone : A 1-year mirror image study with a national claims database in Taiwan. In: Value in Health. 2009 ; Vol. 12, No. SUPPL. 3.
@article{628b0c4c02214c2b9fab7dc02e4e5ca6,
title = "Relapse and long-acting injectable risperidone: A 1-year mirror image study with a national claims database in Taiwan",
abstract = "Objectives: The development of long-acting, injectable atypical antipsychotics has provided a new paradigm for schizophrenia treatment. The study was designed to assess whether a risperidone long-acting injection (RLAI) is associated with reduced relapses and service utilization in the real world. Methods: The Psychiatric Inpatients Medical Claims dataset was used for the analysis. It is a longitudinal dataset that includes the National Health Insurance claims of service uses by a cohort of mentally ill patients. The inclusion criteria for this analysis were patients who: 1) had available information for at least 12 months after the first dose of RLAI; 2) had a primary diagnosis of schizophrenia; and 3) were regularly treated with RLAI for at least 1 year. Patients who accumulatively received at least 75-mg RLAI per 3-month period were considered to be undergoing regular treatment. Wilcoxon signed rank tests were performed to compare differences in numbers of acute admissions, hospital days, emergency room visits, and relapses between the pre- and post-RLAI periods in this 1-year mirror-image study. Results: In total, 108 patients were eligible for analysis. Significant reductions in the total annual numbers of acute hospital admissions by 55{\%} (80 vs. 36, P = 0.0003), hospital days by 48{\%} (4106 vs. 2126, P = 0.0021), and relapses by 54{\%} (115 vs. 53, P = 0.0005) were observed. A reduction of emergency room visits was also observed, but did not reach statistical significance (55 vs. 25, P = 0.1255). Conclusions: This 1-year mirror-image analysis with claims-based data demonstrated that RLAI treatment was associated with reductions in relapses and hospital service utilization.",
keywords = "National Health Insurance, Relapse, Risperidone long-acting injection, Schizophrenia, Taiwan",
author = "Su, {Kuan Pin} and Chang, {Hui Chih} and Tsai, {Shih Jen} and Yen, {Feng Chang} and Tang, {Chao Hsiun}",
year = "2009",
month = "11",
doi = "10.1111/j.1524-4733.2009.00643.x",
language = "English",
volume = "12",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Relapse and long-acting injectable risperidone

T2 - A 1-year mirror image study with a national claims database in Taiwan

AU - Su, Kuan Pin

AU - Chang, Hui Chih

AU - Tsai, Shih Jen

AU - Yen, Feng Chang

AU - Tang, Chao Hsiun

PY - 2009/11

Y1 - 2009/11

N2 - Objectives: The development of long-acting, injectable atypical antipsychotics has provided a new paradigm for schizophrenia treatment. The study was designed to assess whether a risperidone long-acting injection (RLAI) is associated with reduced relapses and service utilization in the real world. Methods: The Psychiatric Inpatients Medical Claims dataset was used for the analysis. It is a longitudinal dataset that includes the National Health Insurance claims of service uses by a cohort of mentally ill patients. The inclusion criteria for this analysis were patients who: 1) had available information for at least 12 months after the first dose of RLAI; 2) had a primary diagnosis of schizophrenia; and 3) were regularly treated with RLAI for at least 1 year. Patients who accumulatively received at least 75-mg RLAI per 3-month period were considered to be undergoing regular treatment. Wilcoxon signed rank tests were performed to compare differences in numbers of acute admissions, hospital days, emergency room visits, and relapses between the pre- and post-RLAI periods in this 1-year mirror-image study. Results: In total, 108 patients were eligible for analysis. Significant reductions in the total annual numbers of acute hospital admissions by 55% (80 vs. 36, P = 0.0003), hospital days by 48% (4106 vs. 2126, P = 0.0021), and relapses by 54% (115 vs. 53, P = 0.0005) were observed. A reduction of emergency room visits was also observed, but did not reach statistical significance (55 vs. 25, P = 0.1255). Conclusions: This 1-year mirror-image analysis with claims-based data demonstrated that RLAI treatment was associated with reductions in relapses and hospital service utilization.

AB - Objectives: The development of long-acting, injectable atypical antipsychotics has provided a new paradigm for schizophrenia treatment. The study was designed to assess whether a risperidone long-acting injection (RLAI) is associated with reduced relapses and service utilization in the real world. Methods: The Psychiatric Inpatients Medical Claims dataset was used for the analysis. It is a longitudinal dataset that includes the National Health Insurance claims of service uses by a cohort of mentally ill patients. The inclusion criteria for this analysis were patients who: 1) had available information for at least 12 months after the first dose of RLAI; 2) had a primary diagnosis of schizophrenia; and 3) were regularly treated with RLAI for at least 1 year. Patients who accumulatively received at least 75-mg RLAI per 3-month period were considered to be undergoing regular treatment. Wilcoxon signed rank tests were performed to compare differences in numbers of acute admissions, hospital days, emergency room visits, and relapses between the pre- and post-RLAI periods in this 1-year mirror-image study. Results: In total, 108 patients were eligible for analysis. Significant reductions in the total annual numbers of acute hospital admissions by 55% (80 vs. 36, P = 0.0003), hospital days by 48% (4106 vs. 2126, P = 0.0021), and relapses by 54% (115 vs. 53, P = 0.0005) were observed. A reduction of emergency room visits was also observed, but did not reach statistical significance (55 vs. 25, P = 0.1255). Conclusions: This 1-year mirror-image analysis with claims-based data demonstrated that RLAI treatment was associated with reductions in relapses and hospital service utilization.

KW - National Health Insurance

KW - Relapse

KW - Risperidone long-acting injection

KW - Schizophrenia

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=72149107845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72149107845&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4733.2009.00643.x

DO - 10.1111/j.1524-4733.2009.00643.x

M3 - Article

VL - 12

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - SUPPL. 3

ER -